11:57 AM EDT, 06/20/2024 (MT Newswires) -- MediPharm Labs ( MEDIF ) , a pharmaceutical company specializing in cannabinoids, on Thursday said it will acquire exclusive rights for advanced cannabis products from Remidose Aerosols.

Under the agreement, MediPharm ( MEDIF ) will license global manufacturing, distribution and sales rights of a novel advanced medical cannabis technology from Remidose.

The products include metered dose inhalers and pressurized sublingual sprays. MediPharm ( MEDIF ) said it already has the equipment and a Good Manufacturing Practice (GMP) facility allowing for these product lines to be manufactured in-house with no material incremental capital costs.

Remidose customers will also be serviced through MediPharm ( MEDIF ) starting in August. These existing customers include Canadian direct-to-patient medical platforms and international medical distributors.

MediPharm ( MEDIF ) plans to use its existing GMP infrastructure, customer channels and wellness sales expertise to expand the customer base of its products in Canada and globally, the company said.

MediPharm's ( MEDIF ) shares were last seen up $0.005 to $0.075 on the Toronto Stock Exchange.